Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2021 Jun 9;25(1):100–108. doi: 10.1038/s41391-021-00393-6

Table 2.

Univariable and multivariable models evaluating expectant management for low-risk prostate cancer, n= 6001 (multivariable).

Variable Level Univariable odds ratio
(95% CI)
p value Multivariable odds ratio
(95% CI)
p value
Age <77
77+
Reference
1.53 (1.30, 1.80)
<0.01 Reference
1.32 (1.19, 1.45)
<0.01
Race White
Black
Other
Reference
0.86 (0.66, 1.12)
1.07 (0.91, 1.25)
0.46 - -
Ethnicity Non-Hispanic
Hispanic
Reference
0.51 (0.40, 0.66)
<0.01 Reference
0.76 (0.67, 0.86)
<0.01
Married/partner Yes
No
Reference
1.13 (0.99, 1.30)
0.07 Reference
1.09 (1.01, 1.16)
0.02
Income (ZIP code median) <$40,000
$40–60,000
>$60,000
Reference
1.42 (1.24, 1.61)
1.79 (1.50, 2.12)
<0.01 Reference
1.26 (1.13, 1.40)
1.37 (1.20, 1.57)
<0.01
Comorbidity 2+
0
1
Reference
1.18 (1.05, 1.33)
1.10 (1.00, 1.21)
0.02 Reference
1.08 (1.01, 1.16)
1.08 (0.99, 1.16)
0.06
PSA (ng/mL) 4–9.9
<4
Reference
1.27 (1.10, 1.48)
<0.01 Reference
1.25 (1.11, 1.41)
<0.01
Derived AJCC stage T2a
T1c
Reference
2.19 (1.91, 2.53)
<0.01 Reference
1.77 (1.60, 1.96)
<0.01
Year of diagnosis 2010
2011
2012
2013
Reference
1.28 (1.15, 1.42)
1.61 (1.49, 1.72)
2.33 (1.98, 2.74)
<0.01 Reference
1.15 (1.05, 1.27)
1.39 (1.30, 1.49)
1.61 (1.43, 1.82)
<0.01